Literature DB >> 30601792

Ischemic Preconditioning, O2 Kinetics, and Performance in Normoxia and Hypoxia.

Chad C Wiggins1,2, Keren Constantini1, Hunter L Paris1, Timothy D Mickleborough1, Robert F Chapman1.   

Abstract

INTRODUCTION: Ischemic preconditioning (IPC) before exercise has been shown to be a novel approach to improve performance in different exercise modes in normoxia (NORM). Few studies have been conducted examining potential mechanisms behind these improvements, and less has been done examining its influence during exercise in hypoxia (HYP). Oxygen uptake and extraction kinetics are factors that have been implicated as possible determinants of cycling performance. We hypothesized that IPC would lead to improvements in oxygen extraction and peripheral blood flow kinetics, and this would translate to improvements in cycling time trial (TT) performance in both NORM and HYP.
METHODS: Thirteen men (age, 24 ± 7 yr; V˙O2max, 63.1 ± 5.1 mL·kg·min) participated in the study. Subjects completed trials of each combination of normobaric HYP (FiO2 = 0.16, simulating ~8000 ft/2500 m) or NORM (FiO2 = 0.21) with preexercise IPC protocol (4 × 5 min at 220 mm Hg) or SHAM procedure. Trials included submaximal constant load cycle exercise bouts (power outputs of 15% below gas exchange threshold, and 85% of V˙O2max), and a 5-km cycling performance TT.
RESULTS: Ischemic preconditioning significantly improved 5-km TT time in NORM by 0.9% ± 1.8% compared with SHAM (IPC, 491.2 ± 35.2 s vs SHAM, 495.9 ± 36.0 s; P < 0.05). Ischemic preconditioning did not alter 5-km TT performance times in HYP (P = 0.231). Ischemic preconditioning did, however, improve tissue oxygen extraction in HYP (deoxygenated hemoglobin/myoglobin: IPC, 21.23 ± 10.95 μM; SHAM, 19.93 ± 9.91 μM; P < 0.05) during moderate-intensity exercise.
CONCLUSIONS: Our data confirm that IPC is an effective ergogenic aid for athletes performing 5-km cycling TT bouts in NORM. Ischemic preconditioning did mitigate the declines in tissue oxygen during moderate-intensity exercise in HYP, but this did not translate to a significant effect on mean group performance. These data suggest that IPC may be of benefit for athletes training and competing in NORM.

Entities:  

Mesh:

Year:  2019        PMID: 30601792     DOI: 10.1249/MSS.0000000000001882

Source DB:  PubMed          Journal:  Med Sci Sports Exerc        ISSN: 0195-9131            Impact factor:   5.411


  5 in total

1.  Seven days of ischemic preconditioning augments hypoxic exercise ventilation and muscle oxygenation in recreationally trained males.

Authors:  Afton D Seeley; Aaron R Caldwell; Lawrence P Cahalin; Soyeon Ahn; Arlette C Perry; Brian Arwari; Kevin A Jacobs
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2022-08-15       Impact factor: 3.210

2.  Ischemic Preconditioning Enhances Aerobic Adaptations to Sprint-Interval Training in Athletes Without Altering Systemic Hypoxic Signaling and Immune Function.

Authors:  Pénélope Paradis-Deschênes; Denis R Joanisse; Pascale Mauriège; François Billaut
Journal:  Front Sports Act Living       Date:  2020-04-28

3.  Ischemic preconditioning of the muscle reduces the metaboreflex response of the knee extensors.

Authors:  Luca Angius; Benjamin Pageaux; Antonio Crisafulli; James Hopker; Samuele Maria Marcora
Journal:  Eur J Appl Physiol       Date:  2021-10-01       Impact factor: 3.078

4.  Remote ischemic preconditioning enhances aerobic performance by accelerating regional oxygenation and improving cardiac function during acute hypobaric hypoxia exposure.

Authors:  Zhifeng Zhong; Huaping Dong; Yu Wu; Simin Zhou; Hong Li; Pei Huang; Huaijun Tian; Xiaoxu Li; Heng Xiao; Tian Yang; Kun Xiong; Gang Zhang; Zhongwei Tang; Yaling Li; Xueying Fan; Chao Yuan; Jiaolin Ning; Yue Li; Jiaxin Xie; Peng Li
Journal:  Front Physiol       Date:  2022-09-09       Impact factor: 4.755

5.  Active Preconditioning With Blood Flow Restriction or/and Systemic Hypoxic Exposure Does Not Improve Repeated Sprint Cycling Performance.

Authors:  Mathias R Aebi; Sarah J Willis; Olivier Girard; Fabio Borrani; Grégoire P Millet
Journal:  Front Physiol       Date:  2019-11-14       Impact factor: 4.566

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.